Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Sutro Biopharma, Inc. - Common Stock (NQ: STRO )

0.8101 -0.4399 (-35.19%)
Streaming Delayed Price Updated: 4:00 PM EDT, Mar 14, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Sutro Biopharma, Inc. - Common Stock

< Previous 1 2 3 Next >
Top movers analysis one hour before the close of the markets on 2025-03-14: top gainers and losers in today's session.
Stay up-to-date with the latest market trends one hour before the close of the markets on Friday. Explore the top gainers and losers during today's session in our detailed report. 
Via Chartmill
Which stocks are experiencing notable movement on Friday?
Looking for insights into the US markets in the middle of the day on Friday? Delve into the top gainers and losers of today's session and gain valuable market intelligence. 
Via Chartmill
12 Health Care Stocks Moving In Friday's Intraday Session
Via Benzinga
Expert Outlook: Sutro Biopharma Through The Eyes Of 6 Analysts
Via Benzinga
A Glimpse Into The Expert Outlook On Sutro Biopharma Through 5 Analysts
Via Benzinga
Peeling Back The Layers: Exploring Sutro Biopharma Through Analyst Insights
Via Benzinga
Penny Stock Sutro Biopharma Cuts Costs, Refocuses Pipeline
Sutro Biopharma reported $62 million in 2024 revenue, down from $153.7 million in 2023, and announced a pipeline restructuring. 
Via Benzinga
Dow Jumps Over 600 Points; US Consumer Sentiment Tumbles In March
Via Benzinga
Topics Stocks
Exposures US Equities
Nasdaq Surges 1.5%; Ulta Beauty Posts Upbeat Results
Via Benzinga
This T-Mobile Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Friday
Via Benzinga
Analyst Expectations For Sutro Biopharma's Future
Via Benzinga
Expert Outlook: Sutro Biopharma Through The Eyes Of 10 Analysts
Via Benzinga
What's Going On With Sutro Biopharma (STRO) Stock?
Sutro Biopharma shares are trading lower by 4.3% during Tuesday's session. The company announced the pricing of an underwritten offering. 
Via Benzinga
Navigating 4 Analyst Ratings For Sutro Biopharma
Via Benzinga
12 Health Care Stocks Moving In Friday's Pre-Market Session
Via Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Why Lyft Shares Are Trading Higher By Over 21%; Here Are 20 Stocks Moving Premarket
Via Benzinga
STRO Stock Earnings: Sutro Biopharma Beats EPS, Beats Revenue for Q2 2024
STRO stock results show that Sutro Biopharma beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
Expert Ratings for Sutro Biopharma
Via Benzinga
Where Sutro Biopharma Stands With Analysts
Via Benzinga
Why Virios Therapeutics Shares Are Trading Lower By Around 48%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Overseas Shipholding, Micron, Squarespace, Incyte And Other Big Stocks Moving Higher On Monday
Via Benzinga
STRO Stock Earnings: Sutro Biopharma Misses EPS, Beats Revenue for Q1 2024
STRO stock results show that Sutro Biopharma missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. 
Via InvestorPlace
Why Kodiak Sciences Shares Are Trading Lower By Around 20%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Kodiak Sciences Inc. (NASDAQ: KOD) fell sharply during Thursday’s session after the company reported a wider-than-expected fourth-quarter loss. Kodiak Sciences posted a quarterly loss of... 
Via Benzinga
REX American Resources Reports Upbeat Earnings, Joins Avalo Therapeutics, RH And Other Big Stocks Moving Higher On Thursday
U.S. stocks were slightly higher, with the S&P 500 gaining around 0.1% on Thursday. Shares of REX American Resources Corporation (NYSE: REX) rose sharply during Thursday’s session following upbeat... 
Via Benzinga
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
Via Benzinga
STRO Stock Earnings: Sutro Biopharma Beats EPS, Beats Revenue for Q4 2023
STRO stock results show that Sutro Biopharma beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
12 Health Care Stocks Moving In Thursday's Pre-Market Session
Via Benzinga
Sutro Biopharma's Lead Ovarian Cancer Candidate Is A Game Changer, Analyst Sees Huge Upside
Oppenheimer initiated coverage on Sutro Biopharma Inc (NASDAQ: STRO), representing around 200% potential upside.  
Via Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For October 6, 2023
Via Benzinga
< Previous 1 2 3 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.